Psoriasis Biologics Face Off in Drug Survival Study
Danish registry data reveal differences in treatment persistence
By
Julie Greenbaum
January 14, 2026
Clinical Scorecard: Psoriasis Biologics Face Off in Drug Survival Study
At a Glance
Category Detail
Condition Psoriasis Key Mechanisms Biologics targeting specific pathways in the immune system. Target Population Adult patients with psoriasis, both bionaive and bioexperienced. Care Setting Routine clinical practice, evaluated through the DERMBIO registry.
Key Highlights
Ustekinumab shows higher drug survival than adalimumab and secukinumab in bionaive patients. Bimekizumab, guselkumab, and risankizumab demonstrate the highest 2-year drug survival in bioexperienced patients. Standardized risk of treatment discontinuation at 5 years is lowest with ustekinumab (37%). 1-year drug survival is lower in bioexperienced patients compared to bionaive patients for several agents. Guideline-Based Recommendations
Diagnosis
Evaluate psoriasis severity and comorbidities, including psoriatic arthritis. Management
Consider biologic therapy based on previous treatment exposure and drug survival data. Monitoring & Follow-up
Regularly assess treatment persistence and patient response to therapy. Risks
Monitor for potential discontinuation rates associated with different biologics. Patient & Prescribing Data
4,438 patients with psoriasis, 23% with comorbid psoriatic arthritis.
Bimekizumab, guselkumab, and risankizumab are preferred for bioexperienced patients due to higher drug survival.
Clinical Best Practices
Utilize data from the DERMBIO registry to inform treatment decisions. Tailor biologic therapy based on patient history of biologic exposure. References
